

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Aug 2026

### Effect of probiotic supplementation on gut microbiota in patients with food addiction and weight regain after bariatric surgery

#### Protocol summary

##### Study aim

Investigating the effect of probiotic supplementation on the change of intestinal microflora

##### Design

This study is a Triple-blind Randomized Controlled Clinical Trial with a parallel group design of 50 patients. A simple method has been used for randomization. Randomization unit is Individual. Excel software has been used for randomization. The central service method was used for allocation concealment.

##### Settings and conduct

The intervention site is Clinic of National Nutrition Research Institute. Study participants, main study researchers, intervention and treatment partners, data collectors, and data analyzers were blinded in this study, and someone outside the study was used for randomization and labeling of probiotic and placebo supplements.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age 18-50 years, weight regain after bariatric surgery, food addiction. Exclusion criteria: Pregnancy, lactation, use of any antibiotics, probiotic product or protein supplement, liver disease, kidney, cancer and thyroid disease, use of weight loss and appetite suppressants.

##### Intervention groups

Intervention group: for 12 weeks, 2 Multi-strain probiotic capsules daily (after breakfast and after lunch) with hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet and ten sessions (Once a week individually) of cognitive behavioral therapy (CBT) intervention (online based). Control group: for 12 weeks, 2 placebo capsules daily (after breakfast and after lunch) with hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet and ten sessions (Once a week individually) of cognitive behavioral therapy (CBT) intervention (online based). Supplements are provided by Tekgen Zist company.

##### Main outcome variables

Abundance of Eubacterium : Akkermansia : Megamonas :

Bifidobacterium : Lactobacillus : Bacteroides

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220406054437N2**

Registration date: **2022-11-14, 1401/08/23**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-11-14, 1401/08/23**

Update count: **0**

##### Registration date

2022-11-14, 1401/08/23

##### Registrant information

##### Name

fateme ghafouri-taleghani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2235 7484

##### Email address

fatima.ghafouri@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-08-06, 1401/05/15

##### Expected recruitment end date

2023-08-06, 1402/05/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

**Scientific title**  
Effect of probiotic supplementation on gut microbiota in patients with food addiction and weight regain after bariatric surgery

**Public title**  
The effect of probiotics on intestinal microbiota

**Purpose**  
Treatment

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
At least 18 months have passed since the date of bariatric surgery and having weight regain of at least 10% of the lowest weight gained Confirmation of food addiction with yale food addiction scale (YFAS) Being in the age range of 18-50 years  
**Exclusion criteria:**  
Pregnancy, lactation, menopause professional athlete Use of any type of antibiotic in the last three weeks Using any type of probiotic product or protein supplement in the last month Having liver diseases (other than fatty liver), kidney, cancer and thyroid diseases Use of weight loss and appetite suppressants

**Age**  
From **18 years** old to **50 years** old

**Gender**  
Both

**Phase**  
N/A

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **50**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
This study is a Triple-blind Randomized Controlled Clinical Trial. A simple method has been used for randomization. Randomization unit is Individual. Excel software has been used for randomization. Using unique codes as ID numbers, and using random numbers generated by the software, participants were randomly assigned to the equal sample size in the intervention and placebo groups. (Description of randomization by Excel software: In the first step, we generated 50 random numbers according to the sample size, in the next step, we obtained the rank of these numbers obtained in the first step, in the third step, we divided these numbers by 25, in the fourth step, the numbers that fell between zero and one were in the intervention group and the rest in the placebo group) The central service method was used for allocation concealment. A person outside the research team allocated unique codes A and B to the supplements, none of the research team members knew which code belonged to the intervention or placebo

group

**Blinding (investigator's opinion)**  
Triple blinded

**Blinding description**  
Study participants, main study researchers, intervention and treatment partners, data collectors, and data analyzers were blinded in this study, and someone outside the study was used for randomization and labeling of probiotic and placebo supplements. The list of random numbers was generated by a statistics professor. It was delivered confidentially to the research team of Tachgen Zist company in Excel form. An unknown person from the research team of Tachgen Zist company was chosen by the company manager as the person responsible for blinding the supplements. Probiotic and placebo supplements were given to the research team in a completely similar shape with Numeric and A/B codes. none of the research team members knew which code belonged to the intervention or placebo group.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of national nutrition and food technology research institute

##### Street address

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

##### City

Tehran

##### Province

Tehran

##### Postal code

1981619573

##### Approval date

2022-03-14, 1400/12/23

##### Ethics committee reference number

IR.SBMU.NNFTRI.REC.1401.024

## Health conditions studied

### 1

#### Description of health condition studied

Food addiction, Weight regain after bariatric surgery

#### ICD-10 code

#### ICD-10 code description

## Primary outcomes

### 1

#### Description

Bacteroides Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

### 2

#### Description

Lactobacillus Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

### 3

#### Description

Bifidobacterium Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

### 4

#### Description

Megamonas Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

### 5

#### Description

Eubacterium Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

### 6

#### Description

Akkermansia Abundance in the stool sample

#### Timepoint

At the beginning of the study and 12 weeks later

#### Method of measurement

Polymerase chain reaction (PCR) in stool samples

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Participants take 2 Multi-strain probiotic capsules daily (after breakfast and after lunch) for 12 weeks. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol. Each probiotic capsule contains Lactobacillus acidophilus ( $1.8 \times 10^9$  CFU / capsule), Bifidobacterium bifidum ( $1.8 \times 10^9$  CFU / capsule), Bifidobacterium lactis ( $1.8 \times 10^9$  CFU / capsule), Bifidobacterium longum / C,  $1.8 (1 \times 10^9$  CFU / capsule), Lactobacillus reuteri ( $1 \times 10^9$  CFU / capsule), magnesium stearate and maltodextrin, produced by Tach Gene Zist Company.

#### Category

Treatment - Other

### 2

#### Description

Control group: Participants in the control group take two placebo capsules (after breakfast and lunch) daily for 12 weeks, containing 300 mg of starch. The capsules are completely similar in shape, size and color to the intervention capsules and are produced by Tach Gene Zist Company. All individuals are given a hypocaloric (-300 to 500 kcal/day), high-protein (25% of energy) diet based on basal metabolism rate (using indirect calorimetry) and level of physical activity (using metabolic equivalents task: MET). For all individuals, ten sessions (Once a week individually) of Cognitive behavioral therapy (CBT) intervention will be performed online based on the Michael Frey protocol.

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

National Nutrition and Food Technology Research Institute

##### Full name of responsible person

Atoosa Saidpour

##### Street address

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

##### City

Tehran

##### Province

Tehran

##### Postal code

1981619573

##### Phone

+98 21 2207 7425

**Email**

atoosa.saidpour@gmail.com

Academic

**2****Recruitment center****Name of recruitment center**

Sina hospital

**Full name of responsible person**

Atoosa Saidpour

**Street address**

Emam Khomeini street, near Hasan Abad square

**City**

Tehran

**Province**

Tehran

**Postal code**

1136746911

**Phone**

+98 21 6634 8500

**Email**

atoosa.saidpour@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Afshin Zarghi

**Street address**

Next to Taleghani Hospital; Yemen Street; Shahid Chamran Highway

**City**

Tehran

**Province**

Tehran

**Postal code**

1985717443

**Phone**

+98 21 2387 1021

**Email**

Zarghi@sbmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding****Person responsible for general inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Atoosa Saidpour

**Position**

Associate Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2207 7425

**Email**

Atoosa.Saidpour@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Atoosa Saidpour

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2207 7425

**Email**

Atoosa.Saidpour@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Fateme Ghafouri-Taleghani

**Position**

phd candidate

**Latest degree**

Master

**Other areas of specialty/work**

Nutrition

**Street address**

No. 7, West Arghavan Ave., Farahzadi Blvd., Qods  
Town

**City**

Tehran

**Province**

Tehran

**Postal code**

1981619573

**Phone**

+98 21 2207 7425

**Email**

fatima.ghafouri@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to  
make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to  
make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to  
make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to  
make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to  
make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to  
make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to  
make this available